ReviewAnnals of nuclear medicine2026
From sensitivity gain to clinical decisions: total-body and long-axial-field-of-view PET/CT for diagnosis and image-based management in oncology and systemic disease.
Review in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Total-body (TB) and long-axial-field-of-view (LAFOV) PET/CT systems provide extended axial coverage and substantially higher sensitivity than conventional PET/CT. This structured narrative review evaluates how that sensitivity is translated into dose reduction, shorter acquisition, dynamic or parametric imaging, delayed imaging, and image-based management in oncology and selected systemic diseases. PubMed/MEDLINE, Embase, Scopus, Web of Science Core Collection, and Cochrane Library were searched for January 2015-April 2026, with a separate ClinicalTrials.gov search; the manuscript was appraised using SANRA. Seventy-four full-text publications were assessed, and 55 principal TB/LAFOV publications informed the synthesis. Evidence is strongest for protocol optimisation, including reduced activity and abbreviated acquisition, but many studies rely on retrospective list-mode subsampling or image-quality endpoints. Recent comparative studies provide early diagnostic-accuracy and management-impact signals, although single-centre design, delayed-imaging confounding, incomplete reference standards, and absent outcome data limit inference. Dynamic imaging, immunoPET, paediatric applications, and post-radioembolisation ⁹⁰Y dosimetry remain promising but early. Multicentre validation, cross-platform harmonisation, patient-centred outcomes, workflow studies, and prospective health-economic evaluation are required.
Indexed as
Identifiers
42734850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.